Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 568.82% and ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...

We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...

Tirzepatide injection (Zepbound, Mounjaro) is officially off the FDA's drug shortage list, meaning compounders can no longer prepare and dispense the drug.

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...

The chip maker invested about $100 million in OpenAI's latest funding round, The Wall Street Journal reports. The CEO will need to convince investors that the company is still more than an auto maker.

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...